Why Mustang Bio, Inc.’s (MBIO) Stock Is Down 10.99%
As of Tuesday, March 04, Mustang Bio, Inc.’s MBIO share price has dipped by 10.99%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
6 Undervalued Biotechnology & Medical Research Stocks for Tuesday, January 17
Discover the top 6 undervalued Biotechnology & Medical Research stocks for Tuesday, January 17 based on AAII’s Stock Grades.Cynthia McLaughlin
Is Mustang Bio Inc (MBIO) Stock a Good Investment?
Learn more about Mustang Bio Inc's (MBIO) stock grades for Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jenna Brashear
Financial Summary
| Share Statistics | MBIO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4.3 | $286.3 | 3% |
|
| Shares Out (Mil) | 6.7 | 54.2 | 16% |
|
| Institutional Ownership | 99.8% | 92.8% | 94% |
|
| Float (Mil) | 5.3 | 39.7 | 13% |
|
| Beta | 2.05 | 0.94 | 93% |
|
| Avg Daily Volume (000s) | 30 | 534 | 23% |
|
| Price Change (52-week) |
(65.1%) | 58.7% | 10% |
|
| Growth | MBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 49.9% | (10.1%) | 94% |
|
| EPS (5yr) | 78.5% | 16.0% | 98 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (66.7%) | (15.6%) | 3% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | MBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($3) | ($43) | 35% |
|
| EPS (TTM) | ($0.463) | ($1.400) | 28% |
|
| Operating Cash Flow (TTM) (Mil) | ($5) | ($31) | 25% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($11) | $160 | 2% |
|
| Valuation | MBIO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.57 | 2.77 | 9% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | MBIO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (21.2%) | (47.3%) | 20% |
|
| ROE | (58.1%) | (55.0%) | 14% |
|
| Liabilities to Assets | 51.7% | 29.6% | 44% |
|
| F-Score | 2 | 2 | 7% |
|
Mustang Bio, Inc. did not pass any screens on 8/20/2026.
